https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbG9tdVZYb3VOU3JxSFFhMFRmQWo4bHZNYXN0QXxBQ3Jtc0tsRkVpVVVjRUtQODFUSUhfdV9hNUxDQ2NFTm9GZ1hUOU9uNWdBRzQ3Mko3OVduSUViRjktSm9nYTR5dE1PM1F5WXkxUzhvTWdiSEVzalFhek52UlBTeUlUbk5QbVYxRldKY3VBZU9Qa3prbE5pNWZrMA&q=http%3A%2F%2Fwww.Gabelli.com%2F&v=r4vuzCARcWQ" target="_blank" rel="nofollow">http://www.Gabelli.com
Invest with Us 1-800-GABELLI (800-422-3554)
Jennie Tsai, the medical device analyst at Gabelli Funds, provides an update on the global orthopedic market. We believe 2023 revenue for most orthopedic companies will be above average as some of the backlog of elective procedures are worked through, companies continue to launch new products and hospital staffing challenges improves. This should result in operating margin improvement for most companies despite higher expenses with inflation and supply chain. Managements are working diligently to drive efficiency and improve margins.